Arja Jukkola-Vuorinen

List of Publications by Year
in descending order

56	4,947	236925 25	168389 53
papers	citations	h-index	g-index

58	58	58	8892
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	How breast cancer recurrences are found â€“ a real-world, prospective cohort study. Acta OncolÃ³gica, 2022, 61, 417-424.	1.8	0
2	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. Journal of Clinical Oncology, 2022, , JCO2102054.	1.6	14
3	Association of Metformin, Other Antidiabetic Medications, and Statins With Incidence of Colon Cancer in Patients With Type 2 Diabetes. Clinical Colorectal Cancer, 2021, 20, e113-e119.	2.3	5
4	Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history. BMJ Open, 2021, 11, e041706.	1.9	2
5	Early-Life Risk Factors for Breast Cancer â€“ Prospective Follow-up in the Northern Finland Birth Cohort 1966. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 616-622.	2.5	0
6	CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Scientific Reports, 2021, 11, 6035.	3.3	42
7	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports, 2021, 11, 10445.	3.3	5
8	Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life settingâ€"initial results. Acta Radiologica Open, 2021, 10, 205846012110306.	0.6	1
9	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
10	Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital. BMJ Open, 2020, 10, e038798.	1.9	12
11	High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. Frontiers in Oncology, 2020, 10, 1470.	2.8	10
12	Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses. Acta OncolÃ³gica, 2020, 59, 1036-1042.	1.8	2
13	Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study. Acta OncolÃ³gica, 2020, 59, 1110-1117.	1.8	12
14	Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer. Tumor Biology, 2019, 41, 101042831984708.	1.8	5
15	High baseline Tie1 level predicts poor survival in metastatic breast cancer. BMC Cancer, 2019, 19, 732.	2.6	12
16	Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer. Anticancer Research, 2019, 39, 5879-5890.	1.1	6
17	Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, e522-e533.	2.4	27
18	Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Research and Treatment, 2019, 175, 741-748.	2.5	9

#	Article	IF	Citations
19	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
20	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
21	Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A. Oncology, 2019, 96, 147-155.	1.9	7
22	Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer. International Journal of Cancer, 2018, 142, 2286-2292.	5.1	15
23	High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. BMC Cancer, 2018, 18, 223.	2.6	25
24	USP28 Deficiency Promotes Breast and Liver Carcinogenesis as well as Tumor Angiogenesis in a HIF-independent Manner. Molecular Cancer Research, 2018, 16, 1000-1012.	3.4	23
25	Longâ€term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clinical Endocrinology, 2018, 88, 303-310.	2.4	47
26	Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study. BMC Cancer, 2017, 17, 72.	2.6	27
27	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. JAMA Oncology, 2017, 3, 793.	7.1	74
28	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. Scientific Reports, 2017, 7, 681.	3.3	20
29	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
30	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
31	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
32	CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. BMC Cancer, 2017, 17, 620.	2.6	29
33	Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility. PLoS Genetics, 2016, 12, e1005816.	3.5	22
34	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
35	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
36	Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. International Journal of Clinical Oncology, 2016, 21, 231-239.	2.2	15

#	Article	IF	Citations
37	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
38	Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.. Journal of Clinical Oncology, 2016, 34, 1001-1001.	1.6	3
39	Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo. Oncotarget, 2016, 7, 87373-87389.	1.8	11
40	Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. Anticancer Research, 2016, 36, 6431-6438.	1.1	21
41	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
42	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
43	KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes. Clinical Cancer Research, 2015, 21, 1591-1601.	7.0	37
44	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
45	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
46	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
47	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
48	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
49	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
50	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
51	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
52	Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology, 2012, 30, 11-18.	1.6	114
53	Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology, The, 2009, 10, 1145-1151.	10.7	65
54	Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocrine-Related Cancer, 2004, 11, 571-579.	3.1	122

#	Article	IF	Citations
55	Aberrant type I and type III collagen gene expression in human breast cancerin vivo. Journal of Pathology, 1998, 186, 262-268.	4.5	216
56	Aberrant type I and type III collagen gene expression in human breast cancer in vivo. , 1998, 186, 262.		2